21120-68-3

Basic information

• Product Name: 4-(4-BROMOPHENOXY)BENZOIC ACID 97
• Synonyms: 4-(4-BROMOPHENOXY)BENZOIC ACID 97
• CAS NO: 21120-68-3
• Molecular Formula: C₁₃H₉BrO₃
• Molecular Weight: 293.115
• Product Categories: C13 to C42+;Carbonyl Compounds;Carboxylic Acids
• Mol File: 21120-68-3.mol
• Article Data: 4

Chemical Properties

• Melting Point: 187-190 °C
• Boiling Point: 407°C at 760 mmHg
• Flash Point: 199.9°C
• Appearance: /
• Density: 1.553g/cm³
• Vapor Pressure: 2.36E-07mmHg at 25°C
• Refractive Index: 1.631
• PKA: 4.27±0.10(Predicted)
• CAS DataBase Reference: 4-(4-BROMOPHENOXY)BENZOIC ACID 97(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-BROMOPHENOXY)BENZOIC ACID 97(21120-68-3)
• EPA Substance Registry System: 4-(4-BROMOPHENOXY)BENZOIC ACID 97(21120-68-3)

Safety Data

• Hazard Codes: Xn,N
• Statements: 22-36-43-50/53
• Safety Statements: 26-36/37-60-61
• RIDADR: UN 3077 9 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 21120-68-3(Hazardous Substances Data)

Usage

General Description

4-(4-Bromophenoxy)benzoic acid 97 is a chemical compound with the molecular formula C13H9BrO3. It is a white to off-white crystalline powder with a purity of 97%. 4-(4-BROMOPHENOXY)BENZOIC ACID 97 is primarily used in research and development of pharmaceuticals and in the manufacturing of agrochemicals. It is also used as an intermediate in organic synthesis and in the production of dyes and pigments. 4-(4-Bromophenoxy)benzoic acid 97 is a versatile compound with applications in various industries.

InChI:InChI=1/C13H9BrO3/c14-10-3-7-12(8-4-10)17-11-5-1-9(2-6-11)13(15)16/h1-8H,(H,15,16)

Upstream product

• 109-72-8 n-butyllithium 
• 60-29-7 diethyl ether 
• 2050-47-7 4,4'-dibromodiphenyl ether 
• 71-43-2 benzene 
• 106-41-2 4-bromo-phenol 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 201230-82-2 carbon monoxide 
• 403-33-8 methyl 4-flurobenzoate 

Downstream Products

• 1357176-18-1 N-(1,1-dioxothian-3-yl)-4-[4-[2-[(5S)-5-hydroxy-1-azabicyclo[2.2.2]oct-5-yl]ethynyl]phenoxy]benzamide 
• 1316759-45-1 C₂₂H₂₅NO₄ 
• 1316759-47-3 C₂₃H₂₃NO₄ 
• 1316759-43-9 C₂₂H₂₃NO₄ 
• 1316759-38-2 C₂₂H₂₁NO₄ 
• 1316759-24-6 4-[4-[2-[(3S)-3-hydroxyquinuclidin-3-yl]ethynyl]phenoxy]benzoic acid 
• 1316759-40-6 C₂₂H₂₁NO₄ 
• 1316759-36-0 C₂₃H₂₅NO₄ 
• 1316759-32-6 C₂₃H₂₃NO₄ 
• 1316759-21-3 methyl 4-[4-[2-[(3S)-3-hydroxyquinuclidin-3-yl]ethynyl]phenoxy]benzoate 
• 1316759-34-8 C₂₃H₂₃NO₄ 
• 1316759-18-8 C₂₇H₂₆N₄O₂ 
• 1316759-16-6 C₂₈H₂₈N₄O₃ 
• 1316759-14-4 C₂₇H₂₈N₄O₃ 

Relevant articles and documents

PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS

This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement C1-mediated disorders.

Evaluation of Novel N-(piperidine-4-yl)benzamide Derivatives as Potential Cell Cycle Inhibitors in HepG2 Cells

In this study, a series of novel N-(piperidine-4-yl)benzamide derivatives was designed, synthesized, and evaluated for antitumor activity. Some compounds were found to have potent antitumor activity. In particular, compound 47 showed the most potent biological activity against HepG2 cells, with an IC50 value of 0.25 μm. Western blot analysis demonstrated that compound 47 inhibited the expression of cyclin B1 and p-Rb and enhanced the expression of p21, p53, Rb, and phospho-adenosine monophosphate-activated protein kinase (p-AMPK). Further, cell cycle arrest was observed by flow cytometry (FCM). In summary, compound 47 was screened to have potential activity for the treatment of hepatocarcinoma via the induction of cell cycle arrest by a p53/p21-dependent pathway.